Vaccine Cell Substrates 2004: National Institutes of Health (NIH), Doubletree Hotel, Rockville, Md., USA, June 29-July 1, 2004
Rebecca Sheets, John C. Petricciani, National Institutes of Health (U.S.), National Institute of Allergy and Infectious Diseases (U.S.)
Karger, 2006 - Medical - 363 pages
This publication comprises the proceedings of the Vaccine Cell Substrates 2004 conference. The purpose of this conference was to review current data and progress in the field of cell substrates, discuss the continued use of existing tests and the appropriateness of new ones at this time, and develop consensus recommendations on how to address these issues, by either recommending implementation or identifying research gaps that preclude decision-making. Scientific topics covered oncogenicity of cellular components, both latent viruses and cellular DNA, viral adventitious agent test methods, level of assurance provided by the current tests, bovine (and porcine) viruses in (primarily) bovine-derived raw materials, and bovine spongiform encephalopathy agents as potential contaminants of cell substrates. Also presented were tests that ensure the safety and quality of novel vaccine cell substrates for investigational vaccine production. Academia, regulators, the vaccine industry and the testing industry developing, regulating or testing viral vaccines will greatly benefit from the wealth of new findings.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Introduction to Vaccine Cell Substrates 2004
Potential Oncogenicity of Cellular
The Uptake and Fate of Exogenous Cellular DNA in Mammalian Cells
21 other sections not shown
Other editions - View all
adenovirus adventitious agents adventitious viruses animal antibodies antigen assay Basel Bethesda biological products bovine serum bovine spongiform encephalopathy BVDV Cancer cattle cell bank cell culture cell lines cell lysate Cell Substrates 2004 cellular DNA clearance clinical continuous cell lines derived detection Dev Biol Basel diploid disease dose evaluation Food and Drug gene therapy genome guidelines hamsters inactivation infection inoculated issue Karger kidney laboratory manufacturing materials MDCK-SF mesothelioma methods monoclonal antibodies mouse mycoplasma negative newborn nude mice oncogenic oral panel pathogen PCR assays Petricciani plasmid polyomavirus porcine positive control potential primer prion protein rats recombinant regulatory replication residual DNA retrovirus risk assessment samples sensitivity sequences serum-free Sheets R eds specific testing tion tissue titre uptake Vaccine Cell Substrates vaccine production vCJD vector Vero cell Vero cell DNA viral contaminants viral safety viruses vitro vivo